Icagen.

PositionTRIANGLE

DURHAM -- A bump in price prevented Icagen shares from losing their Nasdaq listing. The drug developer's price, which had fallen as low as 66 cents in November, needed to close above $1 10 straight...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT